Although protein therapeutics have exceptional potential for nextgeneration therapies, delivery of these macromolecules is hindered due to their vulnerability to biological deactivation, [6-9] poor native membrane permeability, and short circulation time if utilized intravenously. [10-12] For these reasons, the development of protein delivery technologies is a vital endeavor that promises to unlock the potential of this significant class of bioactive macromolecules. [13,14] An emerging strategy to address the challenge of protein delivery is via the use of coacervate particles, which is appealing due to their ability to spontaneously sequester various macromolecular cargoes, [15,16] and to undergo direct cellular interactions. [17] In these terms, coacervates have been described as biomimetic microcontainers due to their physicochemical semblance to the cell cytoplasm, albeit without an external membrane. [18,19] Although being a relative newcomer to the field of therapeutic protein delivery, coacervate-based materials have received significant attention in biomedical research and have already been used for drug delivery. [20,21] For example, coacervate-based materials have shown great promise for controlled growth factor delivery in vivo for attenuation of disc degeneration, persistent angiogenesis, preservation of The extent to which biologic payloads can be effectively delivered to cells is a limiting factor in the development of new therapies. Limitations arise from the lack of pharmacokinetic stability of biologics in vivo. Encapsulating biologics in a protective delivery vector has the potential to improve delivery profile and enhance performance. Coacervate microdroplets are developed as cell-mimetic materials with established potential for the stabilization of biological molecules, such as proteins and nucleic acids. Here, the development of biodegradable coacervate microvectors (comprising synthetically modified amylose polymers) is presented, for the delivery of biologic payloads to cells. Amylose-based coacervate microdroplets are stable under physiological conditions (e.g., temperature and ionic strength), are noncytotoxic owing to their biopolymeric structure, spontaneously interacted with the cell membrane, and are able to deliver and release proteinaceous payloads beyond the plasma membrane. In particular, myoglobin, an oxygen storage and antioxidant protein, is successfully delivered into human mesenchymal stem cells (hMSCs) within 24 h. Furthermore, coacervate microvectors are implemented for the delivery of human bone morphogenetic protein 2 growth factor, inducing differentiation of hMSCs into osteoprogenitor cells. This study demonstrates the potential of coacervate microdroplets as delivery microvectors for biomedical research and the development of new therapies.